🚀 VC round data is live in beta, check it out!
J.B. Chemicals & Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for J.B. Chemicals & Pharma and similar public comparables like Hubei Jumpcan, Zelgen Biopharmaceuticals, CR Pharmaceutical, Kiniksa Pharmaceuticals and more.
J.B. Chemicals & Pharma Overview
About J.B. Chemicals & Pharma
J.B. Chemicals & Pharmaceuticals Ltd is an India-based pharmaceutical company. It manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs). The company's products include various pharmaceutical dosage forms like tablets, injectable, creams, ointments, lozenges, herbal liquids, and capsules. It also offers services including optimization of formulations, scale-up services, stability testing, regulatory support, packaging design, and commercial production. The group derives revenue from the manufacturing and marketing of a diverse range of pharmaceutical products. The company sells its products in India and also exports them to other international countries.
Founded
1976
HQ
Employees
5.5K
Website
Sectors
Financials (LTM)
EV
$4B
J.B. Chemicals & Pharma Financials
J.B. Chemicals & Pharma reported last 12-month revenue of $468M and EBITDA of $128M.
In the same LTM period, J.B. Chemicals & Pharma generated $318M in gross profit, $128M in EBITDA, and $86M in net income.
Revenue (LTM)
J.B. Chemicals & Pharma P&L
In the most recent fiscal year, J.B. Chemicals & Pharma reported revenue of $459M and EBITDA of $122M.
J.B. Chemicals & Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $468M | XXX | $459M | XXX | XXX | XXX |
| Gross Profit | $318M | XXX | $275M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $128M | XXX | $122M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $86M | XXX | $78M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
J.B. Chemicals & Pharma Stock Performance
J.B. Chemicals & Pharma has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
J.B. Chemicals & Pharma's stock price is $22.73.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 0.4% | XXX | XXX | XXX | $0.49 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJ.B. Chemicals & Pharma Valuation Multiples
J.B. Chemicals & Pharma trades at 7.6x EV/Revenue multiple, and 27.8x EV/EBITDA.
EV / Revenue (LTM)
J.B. Chemicals & Pharma Financial Valuation Multiples
As of March 7, 2026, J.B. Chemicals & Pharma has market cap of $4B and EV of $4B.
Equity research analysts estimate J.B. Chemicals & Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
J.B. Chemicals & Pharma has a P/E ratio of 42.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 7.6x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | 27.8x | XXX | 29.2x | XXX | XXX | XXX |
| EV/EBIT | 31.6x | XXX | 35.0x | XXX | XXX | XXX |
| EV/Gross Profit | 11.2x | XXX | 12.9x | XXX | XXX | XXX |
| P/E | 42.5x | XXX | 46.7x | XXX | XXX | XXX |
| EV/FCF | 45.8x | XXX | 41.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified J.B. Chemicals & Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
J.B. Chemicals & Pharma Margins & Growth Rates
J.B. Chemicals & Pharma's revenue in the last 12 month grew by 11%.
J.B. Chemicals & Pharma's revenue per employee in the last FY averaged $0.1M.
J.B. Chemicals & Pharma's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
J.B. Chemicals & Pharma's rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
J.B. Chemicals & Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
J.B. Chemicals & Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hubei Jumpcan | XXX | XXX | XXX | XXX | XXX | XXX |
| Zelgen Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CR Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Kiniksa Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hikma Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
J.B. Chemicals & Pharma M&A Activity
J.B. Chemicals & Pharma acquired XXX companies to date.
Last acquisition by J.B. Chemicals & Pharma was on XXXXXXXX, XXXXX. J.B. Chemicals & Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by J.B. Chemicals & Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJ.B. Chemicals & Pharma Investment Activity
J.B. Chemicals & Pharma invested in XXX companies to date.
J.B. Chemicals & Pharma made its latest investment on XXXXXXXX, XXXXX. J.B. Chemicals & Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by J.B. Chemicals & Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout J.B. Chemicals & Pharma
| When was J.B. Chemicals & Pharma founded? | J.B. Chemicals & Pharma was founded in 1976. |
| Where is J.B. Chemicals & Pharma headquartered? | J.B. Chemicals & Pharma is headquartered in India. |
| How many employees does J.B. Chemicals & Pharma have? | As of today, J.B. Chemicals & Pharma has over 5K employees. |
| Who is the CEO of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's CEO is Nikhil Ashok kumar Chopra. |
| Is J.B. Chemicals & Pharma publicly listed? | Yes, J.B. Chemicals & Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma trades under JBCHEPHARM ticker. |
| When did J.B. Chemicals & Pharma go public? | J.B. Chemicals & Pharma went public in 2003. |
| Who are competitors of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma main competitors are Hubei Jumpcan, Zelgen Biopharmaceuticals, CR Pharmaceutical, Kiniksa Pharmaceuticals. |
| What is the current market cap of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's current market cap is $4B. |
| What is the current revenue of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's last 12 months revenue is $468M. |
| What is the current revenue growth of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of J.B. Chemicals & Pharma? | Current revenue multiple of J.B. Chemicals & Pharma is 7.6x. |
| Is J.B. Chemicals & Pharma profitable? | Yes, J.B. Chemicals & Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's last 12 months EBITDA is $128M. |
| What is J.B. Chemicals & Pharma's EBITDA margin? | J.B. Chemicals & Pharma's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of J.B. Chemicals & Pharma? | Current EBITDA multiple of J.B. Chemicals & Pharma is 27.8x. |
| What is the current FCF of J.B. Chemicals & Pharma? | J.B. Chemicals & Pharma's last 12 months FCF is $78M. |
| What is J.B. Chemicals & Pharma's FCF margin? | J.B. Chemicals & Pharma's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of J.B. Chemicals & Pharma? | Current FCF multiple of J.B. Chemicals & Pharma is 45.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.